Medicine details

ImageBromodel
NameBromodel
DosageTablet
Generic NameBromocriptine
Classes Central Nervous System Agent
Anti-Parkinson Agent
Hormone
Prolactin Inhibitor
Diseases Acromegaly
Galactorrhea
Hormonal Disorder
Menstrual Disorder
Parkinson's Disease
CompanyOpsonin Pharma Limited

Drug Package Details

Strength2.5 mg
Storage Condition
Origin CountryBangladesh
Commercial Pack30
Price per pack301.20
Cost per pack265.06
Package unit10 tabs strip
Price per unit10.04
Cost per unit8.84
Discount0
Coupon
Remarks

Bromocriptine

Bromocriptine belongs to the class of drugs known as dopamine agonists. It acts by stimulating dopamine receptors in the brain, which helps to normalize the levels of dopamine, a neurotransmitter involved in various physiological processes. Its primary mechanism of action is to inhibit the release of prolactin, a hormone responsible for milk production in the breast.

 

Bromocriptine is indicated for the treatment of the following conditions:

  • Hyperprolactinemia: It is used to reduce elevated levels of prolactin in conditions such as prolactin-secreting pituitary tumors (prolactinomas), idiopathic hyperprolactinemia, and functional or neoplastic disorders associated with hyperprolactinemia.
  • Parkinson's disease: Bromocriptine may be used as an adjunctive treatment in Parkinson's disease to improve motor symptoms.
  • Acromegaly: Bromocriptine therapy is indicated in the treatment of acromegaly. Bromocriptine therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. 

 

Hyperprolactinemic Indications:

  • The initial dosage of Bromocriptine in adults is ½ to one 2½ mg scored tablet daily. An additional 2½ mg tablet may be added to the treatment regimen as tolerated every 2-7 days until an optimal therapeutic response is achieved. The therapeutic dosage ranged from 2.5-15 mg daily in adults studied clinically.
  • Based on limited data in children of age 11 to 15, (see Pediatric Use) the initial dose is ½ to one 2½ mg scored tablet daily. Dosing may need to be increased as tolerated until a therapeutic response is achieved. The therapeutic dosage ranged from 2.5-10 mg daily in children with prolactin-secreting pituitary adenomas. 

Acromegaly:

  • The initial recommended dosage is ½ to one 2½ mg Bromocriptine tablet on retiring (with food) for 3 days. An additional ½ to 1 SnapTabs tablet should be added to the treatment regimen as tolerated every 3-7 days until the patient obtains optimal therapeutic benefit. Patients should be reevaluated monthly and the dosage adjusted based on reductions of growth hormone or clinical response. The usual optimal therapeutic dosage range of Bromocriptine varies from 20-30 mg/day in most patients. The maximal dosage should not exceed 100 mg/day. 

 

Side effects associated with bromocriptine include-

  • Nausea and vomiting
  • Headache
  • Dizziness
  • Fatigue
  • Constipation
  • Orthostatic hypotension (low blood pressure upon standing)
  • Dyskinesia (abnormal involuntary movements)
  • Psychiatric disturbances (such as hallucinations, confusion, and psychosis)
  • Peripheral edema (swelling of the extremities)

 

  • Hypotension: Bromocriptine may cause a drop in blood pressure, especially upon standing (orthostatic hypotension). Patients should be cautious when changing positions and should report any dizziness or lightheadedness to their healthcare provider.
  • Psychiatric effects: Psychiatric disturbances, including hallucinations, confusion, and psychosis, have been reported with the use of bromocriptine. Patients should be monitored for any changes in mental status or behavior.
  • Fibrotic complications: Long-term use of bromocriptine has been associated with the development of fibrotic complications, including pleural effusion, pulmonary fibrosis, and retroperitoneal fibrosis. Regular monitoring and assessment of symptoms should be performed.
  • Pregnancy and breastfeeding: Bromocriptine should be used cautiously during pregnancy and breastfeeding. The potential risks and benefits should be discussed with a healthcare professional.

 

Contraindication

Hypersensitivity to bromocriptine or to any of the excipients of Bromocriptine.

 

 

 

  • Bromocriptine is contraindicated in patients with uncontrolled hypertension, hypertensive disorders of pregnancy (including eclampsia, pre-eclampsia or pregnancy-induced hypertension), hypertension post partum and in the puerperium.\
  • Bromocriptine is contraindicated for use in the suppression of lactation or other non-life threatening indications in patients with a history of coronary artery disease, or other severe cardiovascular conditions, or symptoms / history of severe psychiatric disorders.
  • Patients with these underlying conditions taking Bromocriptine for the indication of macro-adenomas should only take it if the perceived benefits outweigh the potential risks